Comparable stake leader
Heng Fai Ambrose Chan
SEC ownership of IMPACT BIOMEDICAL INC.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001834105.
Disclosed value leader
GEODE CAPITAL MANAGEMENT, LLC
Comparable rows
1/24
Latest evidence
30 Jun 2026
- Public ticker
- IBO on NYSE
- Parsed ownership sources
-
13D/G, 3/4/5, and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Heng Fai Ambrose Chan
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
1 of 24
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Heng Fai Ambrose Chan
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001834105
- Issuer location
- Houston, TX
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of IMPACT BIOMEDICAL INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Heng Fai Ambrose Chan
Disclosed value leader
GEODE CAPITAL MANAGEMENT,...
Comparable rows
1/24
Latest evidence
30 Jun 2026
13D/G
3/4/5
13F
Lead comparable stake: 2.9%
23 rows are not safely comparable across share classes.
13D/G row: Heng Fai Ambrose Chan
Showing 1-8 of 24 holder rows.
Quick read
Heng Fai Ambrose Chan leads the comparable SEC ownership view at 2.9%.
1 of 24 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Heng Fai Ambrose Chan's linked filing trail.
Comparable ownership
Top 1
Heng Fai Ambrose Chan
2.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 24 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Heng Fai Ambrose Chan |
13D/G
|
2.9%
|
—
351,555 shares
|
$0 | 02 Apr 2025 |
| DSS, INC. |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$294,476
545,024 shares
|
— | 22 May 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$545,578
1,185,163 shares
|
— | 30 Jun 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$371,997
808,689 shares
|
— | 30 Jun 2026 |
| STATE STREET CORP |
13F
Company
|
—
class O/S missing
|
$279,633
607,897 shares
|
— | 30 Jun 2026 |
| VANGUARD FIDUCIARY TRUST CO |
13F
Company
|
—
class O/S missing
|
$271,137
589,428 shares
|
— | 30 Jun 2026 |
| Frank D. Heuszel |
3/4/5
Chief Executive Officer, Director
|
—
class O/S missing
|
$219,783
97,344 shares
|
— | 05 Dec 2024 |
| Jason Grady |
3/4/5
Director
|
—
class O/S missing
|
$162,643
250,182 shares
|
-$32,505 | 23 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$57,835.
Buys
$0
Insiders: 0
Sells
$57,835
Insiders: 2
Net
-$57,835
Shares: -95,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 95,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 95,000 | $0 | $57,835 | -$57,835 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-11 of 11 reporting-owner rows connected to IMPACT BIOMEDICAL INC.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
11
Largest Forms 3/4/5 holder
DSS, INC.
Net 12M change
-$57,835
Latest report
25 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| DSS, INC. | 10%+ Owner | $294,476 | Filing P/S | 22 May 2025 | ||
| Frank D. Heuszel | Chief Executive Officer, Director | $219,783 | Filing P/S | 05 Dec 2024 | ||
| Jason Grady | Director | $162,643 | -$32,505 | -17% | Filing P/S | 23 Mar 2026 |
| Todd D. Macko | Chief Financial Officer | $87,101 | -$25,330 | -23% | Filing P/S | 25 Mar 2026 |
| Heng Fai Ambrose Chan | Director | $0 | Mixed | 03 Apr 2025 | ||
| Christian Thomas Zimmerman | Director | Mixed | 16 Sep 2024 | |||
| David K. Keene | Director | Mixed | 16 Sep 2024 | |||
| Melissa Kaye Sims | Director | Mixed | 16 Sep 2024 | |||
| Mark Suseck | Chief Operating Officer | Mixed | 16 Sep 2024 | |||
| Castel Berisford Hibbert | Director | Mixed | 16 Sep 2024 | |||
| Elise Brownell | Director | Mixed | 16 Sep 2024 |
Recent insider transactions for IMPACT BIOMEDICAL INC.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Todd D. Macko | IBO | Common Stock | Sale | -21.9% | $24,369 | $0.5615 | -43,400 | 155,122 | 27 Mar 2026 | Direct |
| Todd D. Macko | IBO | Common Stock | Sale | -0.8% | $961 | $0.6008 | -1,600 | 198,122 | 25 Mar 2026 | Direct |
| Jason Grady | IBO | Common Stock | Sale | -16.7% | $32,505 | $0.6501 | -50,000 | 250,182 | 23 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.